Genmab A/S (0MGB) Share Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0MGB Analyst Ratings

Moderate Buy

3 Buy

3 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Genmab

A/S

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0MGB Stock 12 Month Forecast

Average Price Target

kr1,993.75

▲(26.95% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is kr1,993.75 with a high forecast of kr2,600.00 and a low forecast of kr1,500.00. The average price target represents a 26.95% change from the last price of kr1,570.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1295":"kr1,295","1948":"kr1,948","2601":"kr2,601","1621.5":"kr1,621.5","2274.5":"kr2,274.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1993.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.99K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1295,1621.5,1948,2274.5,2601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1387.14,1480.4369230769232,1573.7338461538461,1667.0307692307692,1760.3276923076924,1853.6246153846155,1946.9215384615386,2040.2184615384615,2133.5153846153844,2226.8123076923075,2320.1092307692306,2413.4061538461538,2506.703076923077,{"y":2600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1387.14,1433.8023076923077,1480.4646153846154,1527.126923076923,1573.789230769231,1620.4515384615386,1667.1138461538462,1713.7761538461539,1760.4384615384615,1807.1007692307694,1853.7630769230768,1900.4253846153847,1947.0876923076924,{"y":1993.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1387.14,1395.8215384615385,1404.503076923077,1413.1846153846154,1421.866153846154,1430.5476923076924,1439.2292307692308,1447.9107692307693,1456.5923076923077,1465.273846153846,1473.9553846153847,1482.636923076923,1491.3184615384616,{"y":1500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1738.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1963.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1869.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1621.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1547,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1552.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1491.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1422.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1608.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1296.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1401.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1420.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1387.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr2,600

Average Price Targetkr1,994

Lowest Price Targetkr1,500

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shirley Chen

Barclays

kr1,875

Buy

19.39%

Upside

Reiterated

08/19/25

Barclays Sticks to Its Buy Rating for Genmab A/S (0MGB)

Xian Deng

UBS

kr2,500→kr2,600

Buy

65.55%

Upside

Reiterated

08/13/25

UBS Keeps Their Buy Rating on Genmab A/S (0MGB)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

08/11/25

Genmab A/S (0MGB) Receives a Hold from Goldman Sachs

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)Reported 2Q25 results and we remain Hold-rated.

James Gordon

J.P. Morgan

kr1,700→kr1,500

Hold

-4.49%

Downside

Reiterated

06/06/25

J.P. Morgan Remains a Hold on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

kr2,300→kr2,000

Buy

27.35%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

kr1,900→kr1,750

Buy

11.43%

Upside

Reiterated

05/23/25

Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK17.50 at Deutsche BankDeutsche Bank analyst Emmanuel Papadakis lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK17.50 (from DKK19.00) while maintaining a Buy rating.

Sachin Jain

Bank of America Securities

kr2,285

Buy

45.50%

Upside

Reiterated

05/20/25

Genmab's Strategic Forecast and Pipeline Potential Drive Buy Rating

Michael Novod CFA

Nordea Markets

Not Ranked

Nordea Markets

kr2,009

Buy

27.92%

Upside

Upgraded

05/09/25

Genmab upgraded to Buy from Hold at NordeaGenmab upgraded to Buy from Hold at Nordea

Rajesh Kumar

HSBC

kr2,970→kr1,990

Buy

26.71%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

kr1,400→kr1,300

Hold

-17.22%

Downside

Reiterated

04/16/25

Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,300 at BNP Paribas ExaneBNP Paribas Exane analyst Victor Floch lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK1,300.00 (from DKK1,400.00) while maintaining a Neutral rating.

Justin Smith

Bernstein

kr1,000

Sell

-36.33%

Downside

Downgraded

04/01/25

Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns

Brian Balchin

Jefferies

kr1,650

Hold

5.06%

Upside

Reiterated

12/10/24

Qize Ding

Redburn Atlantic

kr2,899

Buy

84.59%

Upside

Initiated

10/08/24

Genmab initiated with a Buy at Redburn AtlanticGenmab initiated with a Buy at Redburn Atlantic

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shirley Chen

Barclays

kr1,875

Buy

19.39%

Upside

Reiterated

08/19/25

Barclays Sticks to Its Buy Rating for Genmab A/S (0MGB)

Xian Deng

UBS

kr2,500→kr2,600

Buy

65.55%

Upside

Reiterated

08/13/25

UBS Keeps Their Buy Rating on Genmab A/S (0MGB)

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

08/11/25

Genmab A/S (0MGB) Receives a Hold from Goldman Sachs

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)Reported 2Q25 results and we remain Hold-rated.

James Gordon

J.P. Morgan

kr1,700→kr1,500

Hold

-4.49%

Downside

Reiterated

06/06/25

J.P. Morgan Remains a Hold on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

kr2,300→kr2,000

Buy

27.35%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

kr1,900→kr1,750

Buy

11.43%

Upside

Reiterated

05/23/25

Sachin Jain

Bank of America Securities

kr2,285

Buy

45.50%

Upside

Reiterated

05/20/25

Genmab's Strategic Forecast and Pipeline Potential Drive Buy Rating

Michael Novod CFA

Nordea Markets

Not Ranked

Nordea Markets

kr2,009

Buy

27.92%

Upside

Upgraded

05/09/25

Genmab upgraded to Buy from Hold at NordeaGenmab upgraded to Buy from Hold at Nordea

Rajesh Kumar

HSBC

kr2,970→kr1,990

Buy

26.71%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

kr1,400→kr1,300

Hold

-17.22%

Downside

Reiterated

04/16/25

Justin Smith

Bernstein

kr1,000

Sell

-36.33%

Downside

Downgraded

04/01/25

Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns

Brian Balchin

Jefferies

kr1,650

Hold

5.06%

Upside

Reiterated

12/10/24

Qize Ding

Redburn Atlantic

kr2,899

Buy

84.59%

Upside

Initiated

10/08/24

Genmab initiated with a Buy at Redburn AtlanticGenmab initiated with a Buy at Redburn Atlantic

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab A/S

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

-0.64%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of -0.64% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+4.32%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +4.32% per trade.

1 Year

Emmanuel PapadakisDeutsche Bank

Success Rate

11/17 ratings generated profit

Average Return

+6.14%

reiterated a buy rating 3 months ago

Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +6.14% per trade.

2 Years

xxx

Success Rate

13/17 ratings generated profit

Average Return

+9.22%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.47% of your transactions generating a profit, with an average return of +9.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MGB Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0MGB has received 13 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0MGB average Analyst price target in the past 3 months is 1,993.75.

Each month's total comprises the sum of three months' worth of ratings.

0MGB Financial Forecast

0MGB Earnings Forecast

Next quarter’s earnings estimate for 0MGB is kr28.32 with a range of kr21.97 to kr36.32. The previous quarter’s EPS was kr34.71. 0MGB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.05% of the time in the same period. In the last calendar year 0MGB has Outperformed its overall industry.

0MGB Sales Forecast

Next quarter’s sales forecast for 0MGB is kr6.20B with a range of kr5.94B to kr6.50B. The previous quarter’s sales results were kr6.08B. 0MGB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year 0MGB has Outperformed its overall industry.

0MGB Stock Forecast FAQ

What is GB:0MGB’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is 1,993.75.

What is GB:0MGB’s upside potential, based on the analysts’ average price target?

Genmab A/S has 26.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genmab A/S a Buy, Sell or Hold?

Genmab A/S has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.

What is Genmab A/S’s share price target?

The average share price target for Genmab A/S is 1,993.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr2,600.00 ,and the lowest forecast is kr1,500.00. The average share price target represents 26.95% Increase from the current price of kr1,570.5.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Genmab A/S?

To buy shares of GB:0MGB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Genmab A/S (0MGB) Share Forecast & Price Target

0MGB Analyst Ratings

0MGB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab A/S

0MGB Analyst Recommendation Trends

0MGB Financial Forecast

0MGB Earnings Forecast

0MGB Sales Forecast

0MGB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts